2-Methyl-1,4,5,6-tetrahydro-cyclopentaimidazole | 24374-30-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-Methyl-1,4,5,6-tetrahydro-cyclopentaimidazole
• 英文别名: 2-Methyl-1,4,5,6-tetrahydrocyclopenta[d]imidazole
• CAS: 24374-30-9
• 化学式: C₇H₁₀N₂
• 分子量: 122.17
• InChiKey: FZTAHPMAKYDRNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Multi-cyclic cinnamide derivatives
  申请人：Kimura Teiji

  公开号：US20070219181A1

  公开（公告）日：2007-09-20

  The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar 2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X 1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  本发明提供了一种由以下公式（I）表示的化合物或其药理学上可接受的盐，其中Ar1代表可能用C1-6烷基等取代的咪唑基团，Ar2代表可能用C1-6烷氧基等取代的苯基团，X1代表双键等，Het代表可能用C1-6烷基等取代的咪唑基团，该化合物对由Aβ引起的疾病具有治疗或预防作用。
• MULTI-CYCLIC CINNAMIDE DERIVATIVES
  申请人：KIMURA Teiji

  公开号：US20100168095A1

  公开（公告）日：2010-07-01

  The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  本发明提供了一种化合物，其化学式表示为(I)：或其药学上可接受的盐，其中Ar1代表可被C1-6烷基等取代的咪唑基团，Ar2代表可被C1-6烷氧基等取代的苯基团，X1代表双键等，Het代表可被C1-6烷基等取代的咪唑基团，该化合物对由Aβ引起的疾病具有治疗或预防作用。
• ANTIVIRAL COMPOUNDS
  申请人：Guo Hongyan

  公开号：US20130137877A1

  公开（公告）日：2013-05-30

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  这项发明涉及抗病毒化合物、含有这些化合物的组合物、包括给予这些化合物的治疗方法，以及用于制备这些化合物的过程和中间体。
• Beta secretase inhibitor
  申请人：Mimoto Tsutomu

  公开号：US20090198056A1

  公开（公告）日：2009-08-06

  The present invention relates to a compound of the formula (1): wherein R 1 is group of the formula (2): (wherein X is nitrogen atom or C(R 5 ), Y is nitrogen atom or C(R 6 ), R 5 and R 6 are each independently hydrogen atom, etc.) etc., m is 1 to 6, L 1 is single bond, etc., R 2 is hydrogen atom, substituted or unsubstituted alkyl group, etc., R 3 is hydrogen atom, etc., L 2 is single bond, etc., R 4 is hydrogen atom, substituted or unsubstituted aryl group, etc., or pharmaceutically acceptable salt thereof, being useful for preventing or treating Alzheimer's disease.

  本发明涉及一种化合物，其化学式为（1）：其中R1是化合物（2）的基团：（其中X是氮原子或C（R5），Y是氮原子或C（R6），R5和R6分别独立地是氢原子等），m为1到6，L1为单键等，R2为氢原子，取代或未取代的烷基等，R3为氢原子等，L2为单键等，R4为氢原子，取代或未取代的芳基等，或其药学上可接受的盐，可用于预防或治疗阿尔茨海默病。
• PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS
  申请人：Incyte Corporation

  公开号：EP3792256A1

  公开（公告）日：2021-03-17

  The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

  本公开提供了式 I 的化合物或其药学上可接受的盐，它们能调节磷酸肌醇 3-激酶-γ（PI3Kγ）的活性，可用于治疗与 PI3Kγ 活性有关的疾病，例如包括自身免疫性疾病、癌症、心血管疾病和神经退行性疾病。